{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T07:58:01Z","timestamp":1790927881909,"version":"4.1.0"},"reference-count":50,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:p>\n                    This study investigated genetic determinants of the pharmacokinetics of the CYP2C8 index drugs repaglinide and gemfibrozil, and their interaction in healthy participants. Sequencing data from a study with montelukast revealed a novel functional\n                    <jats:italic>CYP2C8<\/jats:italic>\n                    allele (rs2071426,\n                    <jats:italic>CYP2C8*19<\/jats:italic>\n                    ), predicted to create an intronic splice donor site. In human liver samples,\n                    <jats:italic>CYP2C8*19<\/jats:italic>\n                    associated with transcript\u2010specific changes in\n                    <jats:italic>CYP2C8<\/jats:italic>\n                    mRNA expression, reduced CYP2C8 protein expression, and decreased enzyme activity. Consistently, participants with the\n                    <jats:italic>CYP2C8*19<\/jats:italic>\n                    \/\n                    <jats:italic>*19<\/jats:italic>\n                    genotype had 45% greater area under the plasma repaglinide concentration\u2013time curve from time zero to infinity (AUC\n                    <jats:sub>0\u2010\u221e<\/jats:sub>\n                    ) than participants with\n                    <jats:italic>CYP2C8*1<\/jats:italic>\n                    \/\n                    <jats:italic>*1<\/jats:italic>\n                    (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20091.6\u2009\u00d7\u200910\n                    <jats:sup>\u22124<\/jats:sup>\n                    ). Participants with\n                    <jats:italic>CYP2C8*1<\/jats:italic>\n                    \/\n                    <jats:italic>*3<\/jats:italic>\n                    had 26% smaller AUC\n                    <jats:sub>0\u2010\u221e<\/jats:sub>\n                    (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.0033) and those with\n                    <jats:italic>CYP2C8*1<\/jats:italic>\n                    \/\n                    <jats:italic>*4<\/jats:italic>\n                    had 51% greater AUC\n                    <jats:sub>0\u2010\u221e<\/jats:sub>\n                    (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20098.2\u2009\u00d7\u200910\n                    <jats:sup>\u22124<\/jats:sup>\n                    ). The fold increase in repaglinide AUC\n                    <jats:sub>0\u2010\u221e<\/jats:sub>\n                    caused by gemfibrozil was 36% (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20091.3\u2009\u00d7\u200910\n                    <jats:sup>\u22124<\/jats:sup>\n                    ) smaller in\n                    <jats:italic>CYP2C8*19<\/jats:italic>\n                    \/\n                    <jats:italic>*19<\/jats:italic>\n                    participants than in\n                    <jats:italic>CYP2C8*1<\/jats:italic>\n                    \/\n                    <jats:italic>*1<\/jats:italic>\n                    participants. In a genome\u2010wide association study (GWAS),\n                    <jats:italic>SLCO1B1<\/jats:italic>\n                    c.521\u2009T&gt;C (rs4149056) associated with increased repaglinide AUC\n                    <jats:sub>0\u2010\u221e<\/jats:sub>\n                    (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20094.5\u2009\u00d7\u200910\n                    <jats:sup>\u221215<\/jats:sup>\n                    ;\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009172) and\n                    <jats:italic>SLCO1A2<\/jats:italic>\n                    variants associated with decreased AUC\n                    <jats:sub>0\u2010\u221e<\/jats:sub>\n                    (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u200910\n                    <jats:sup>\u22128<\/jats:sup>\n                    ). In a GWAS of repaglinide after gemfibrozil pretreatment,\n                    <jats:italic>SLCO1C1<\/jats:italic>\n                    variants associated with decreased AUC\n                    <jats:sub>0\u2010\u221e<\/jats:sub>\n                    (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20091.6\u2009\u00d7\u200910\n                    <jats:sup>\u22128<\/jats:sup>\n                    ;\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200966). Participants with the poor function\n                    <jats:italic>SLCO1B1<\/jats:italic>\n                    genotype showed a 32% smaller fold increase in repaglinide AUC\n                    <jats:sub>0\u2010\u221e<\/jats:sub>\n                    following gemfibrozil than participants with the normal function\n                    <jats:italic>SLCO1B1<\/jats:italic>\n                    genotype (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.0045). This study characterizes\n                    <jats:italic>CYP2C8*19<\/jats:italic>\n                    as a novel decreased function allele and shows that\n                    <jats:italic>CYP2C8<\/jats:italic>\n                    and\n                    <jats:italic>SLCO1B1<\/jats:italic>\n                    genotypes affect the gemfibrozil\u2013repaglinide interaction.\n                  <\/jats:p>","DOI":"10.1002\/cpt.70376","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T03:53:08Z","timestamp":1782964388000},"page":"966-978","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Identification of a Functional\n                    <scp>\n                      <i>CYP2C8<\/i>\n                    <\/scp>\n                    Variant Allele that Alters Splicing, Reduces Protein Expression, and Increases Drug Exposure"],"prefix":"10.1002","volume":"120","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3348-1325","authenticated-orcid":false,"given":"Anssi J. H.","family":"Mykk\u00e4nen","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology University of Helsinki  Helsinki Finland"},{"name":"Department of Clinical Pharmacology, HUS Diagnostic Center Helsinki University Hospital  Helsinki Finland"},{"name":"Individualized Drug Therapy Research Program University of Helsinki  Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9125-5716","authenticated-orcid":false,"given":"P\u00e4ivi","family":"Hirvensalo","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology University of Helsinki  Helsinki Finland"},{"name":"Individualized Drug Therapy Research Program University of Helsinki  Helsinki Finland"},{"name":"Integrative Physiology and Pharmacology, Institute of Biomedicine University of Turku  Turku Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9819-2773","authenticated-orcid":false,"given":"Kathrin","family":"Klein","sequence":"additional","affiliation":[{"name":"Dr. Margarete Fischer\u2010Bosch Institute of Clinical Pharmacology  Stuttgart Germany"},{"name":"University of Tuebingen  Tuebingen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1829-576X","authenticated-orcid":false,"given":"Dorota","family":"Kaminska","sequence":"additional","affiliation":[{"name":"Institute of Public Health and Clinical Nutrition University of Eastern Finland  Kuopio Finland"},{"name":"Department of Medicine, Division of Digestive Diseases UCLA  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Grube","sequence":"additional","affiliation":[{"name":"Department of General Pharmacology University Medicine Greifswald  Greifswald Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4562-9606","authenticated-orcid":false,"given":"Tuija","family":"Tapaninen","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology University of Helsinki  Helsinki Finland"},{"name":"Department of Clinical Pharmacology, HUS Diagnostic Center Helsinki University Hospital  Helsinki Finland"},{"name":"Individualized Drug Therapy Research Program University of Helsinki  Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4089-7209","authenticated-orcid":false,"given":"Johanna I.","family":"Kiiski","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology University of Helsinki  Helsinki Finland"},{"name":"Department of Clinical Pharmacology, HUS Diagnostic Center Helsinki University Hospital  Helsinki Finland"},{"name":"Individualized Drug Therapy Research Program University of Helsinki  Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7627-1638","authenticated-orcid":false,"given":"Mikko","family":"Neuvonen","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology University of Helsinki  Helsinki Finland"},{"name":"Individualized Drug Therapy Research Program University of Helsinki  Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0735-400X","authenticated-orcid":false,"given":"Ville T.","family":"M\u00e4nnist\u00f6","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine University of Eastern Finland and Kuopio University Hospital  Kuopio Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6241-6859","authenticated-orcid":false,"given":"Jussi","family":"Pihlajam\u00e4ki","sequence":"additional","affiliation":[{"name":"Institute of Public Health and Clinical Nutrition University of Eastern Finland  Kuopio Finland"},{"name":"Department of Medicine, Endocrinology and Clinical Nutrition Kuopio University Hospital  Kuopio Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1670-5534","authenticated-orcid":false,"given":"Mladen","family":"Tzvetkov","sequence":"additional","affiliation":[{"name":"Department of General Pharmacology University Medicine Greifswald  Greifswald Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9984-075X","authenticated-orcid":false,"given":"Matthias","family":"Schwab","sequence":"additional","affiliation":[{"name":"Dr. Margarete Fischer\u2010Bosch Institute of Clinical Pharmacology  Stuttgart Germany"},{"name":"Departments of Clinical Pharmacology, and of Biochemistry and Pharmacy University Tuebingen  Tuebingen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5713-5692","authenticated-orcid":false,"given":"Aleksi","family":"Tornio","sequence":"additional","affiliation":[{"name":"Integrative Physiology and Pharmacology, Institute of Biomedicine University of Turku  Turku Finland"},{"name":"Unit of Clinical Pharmacology Turku University Hospital  Turku Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9577-2788","authenticated-orcid":false,"given":"Janne T.","family":"Backman","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology University of Helsinki  Helsinki Finland"},{"name":"Department of Clinical Pharmacology, HUS Diagnostic Center Helsinki University Hospital  Helsinki Finland"},{"name":"Individualized Drug Therapy Research Program University of Helsinki  Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4550-2189","authenticated-orcid":false,"given":"Mikko","family":"Niemi","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology University of Helsinki  Helsinki Finland"},{"name":"Department of Clinical Pharmacology, HUS Diagnostic Center Helsinki University Hospital  Helsinki Finland"},{"name":"Individualized Drug Therapy Research Program University of Helsinki  Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"e_1_2_10_1_1","unstructured":"International Council for Harmonisation of Technical Requirement for Pharmaceuticals for Human Use.Drug Interaction Studies M12(2024) <https:\/\/database.ich.org\/sites\/default\/files\/ICH_M12_Step4_Guideline_2024_0521_0.pdf>."},{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.0306-5251.2003.01862.x"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.115.011411"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-003-1034-7"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.02027.x"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2005.07.005"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2005.11.002"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2005.01.018"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-012-0956-5"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.109.029728"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.111.040931"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2010.358"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2010.73"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.04086.x"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2013.92"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2005.04.007"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-007-0273-9"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-006-0133-z"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-003-1181-x"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2014.141"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3610"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.34"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.74"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.313"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270007311569"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2008.03287.x"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(03)00228-5"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1086\/319501"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1086\/428594"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2321"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2429"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.116.069807"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2053"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.3c00040"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1630"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.891"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2015.00261"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.117.078626"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1186\/gm405"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1101\/gr.266932.120"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaz1776"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-0716-1554-6_7"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.113.053819"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1260419"},{"key":"e_1_2_10_45_1","unstructured":"The Human Protein Atlas<https:\/\/www.proteinatlas.org\/>."},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13386"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs-2018-0162"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.109.030866"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature15393"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1292"}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.70376","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpt.70376","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.70376","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T07:50:55Z","timestamp":1790927455000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.70376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1002\/cpt.70376"],"URL":"https:\/\/doi.org\/10.1002\/cpt.70376","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"2025-11-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}